YewMaker, a healthcare technology company, has revealed the results of a survey they conducted, which showed strong public support for transparency and action on the carbon emissions of medicines.
Their survey, conducted across the UK, US, Australia and France revealed that 84% of respondents want medicine manufacturers to disclose the carbon footprint of their products and 84% want healthcare to actively reduce the carbon emissions of medicines and prioritise suppliers with a lower carbon footprint, if the costs are not higher.
The NHS has committed to achieve net zero carbon emissions by 2045, making it essential to address medicine-related emissions, which account for a quarter of the NHS carbon footprint.
The survey also found that 73% of respondents believe it is important for doctors to have access to carbon footprint information when prescribing medicines and 53% of participants said they personally wish to receive information about the carbon footprint of the medicines they consume.
Nazneen Rahman, CEO at YewMaker, commented: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions. YewMaker is developing MCF Classifier to provide standardised carbon footprints for thousands of medicines, equipping healthcare professionals with the knowledge they need to make carbon-informed decisions about medicines.”
MCF Classifier, which is supported by SBRI Healthcare and the Greener NHS, harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines, categorised into four MCF Ratings. YewMaker is set to launch the MCF Formulary, a user-friendly web application, in early 2024, making the MCF Ratings accessible to all.
A new survey conducted by YewMaker, a healthcare technology company, has revealed strong public support for transparency and action on the carbon emissions of medicines.
The survey, which was conducted across the UK, US, Australia and France, revealed that 84% of respondents want medicine manufacturers to disclose the carbon footprint of their products and 84% want healthcare to actively reduce the carbon emissions of medicines and prioritise suppliers with a lower carbon footprint, if the costs are not higher.
Nazneen Rahman, CEO at YewMaker, said: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions. YewMaker is developing MCF Classifier to provide standardised carbon footprints for thousands of medicines, equipping healthcare professionals with the knowledge they need to make carbon-informed decisions about medicines.”
The NHS has committed to achieve net zero carbon emissions by 2045, making it essential to address medicine-related emissions, which account for a quarter of the NHS carbon footprint. MCF Classifier, which is supported by SBRI Healthcare and the Greener NHS, harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines, categorised into four MCF Ratings. YewMaker is set to launch the MCF Formulary, a user-friendly web application, in early 2024, making the MCF Ratings accessible to all.
Commenting on the findings, Nazneen Rahman said: “This survey demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines. YewMaker’s MCF Classifier will provide standardised carbon footprints for thousands of medicines, equipping healthcare professionals with the knowledge they need to make carbon-informed decisions about medicines.”
The post Study Finds that Nearly All People Support Pharmaceutical Companies Disclosing Carbon Footprint of Their Products first appeared on BusinessMole.
